Stockscreener 앱 받기
150.06
2.56%
3.74
시간 외 거래:
150.06
전일 마감가:
$146.32
열려 있는:
$148.26
하루 거래량:
195.53K
Relative Volume:
1.28
시가총액:
$2.90B
수익:
$152.42M
순이익/손실:
$45.24M
주가수익비율:
59.78
EPS:
2.51
순현금흐름:
$6.97M
1주 성능:
+13.07%
1개월 성능:
+30.35%
6개월 성능:
+30.27%
1년 성능:
+54.83%
1일 변동 폭
$143.50
$151.55
1주일 범위
$131.67
$151.55
52주 변동 폭
$93.58
$151.55
리간드 파마 Stock (LGND) Company Profile
명칭
Ligand Pharmaceuticals Inc
전화
858-550-7500
주소
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
150.06 | 2.75B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
리간드 파마 Stock (LGND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Stifel | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 재개 | Stephens | Overweight |
| 2021-02-04 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-06 | 개시 | Barclays | Overweight |
| 2020-03-24 | 다운그레이드 | Argus | Buy → Hold |
| 2020-03-10 | 개시 | Guggenheim | Neutral |
| 2020-02-06 | 개시 | The Benchmark Company | Buy |
| 2019-09-19 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-03 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-06 | 재확인 | H.C. Wainwright | Buy |
| 2018-10-29 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-11 | 재확인 | Argus | Buy |
| 2018-08-17 | 개시 | Goldman | Neutral |
| 2018-08-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 개시 | Argus | Buy |
| 2017-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-05 | 재개 | H.C. Wainwright | Buy |
| 2016-10-05 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-05 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 개시 | Sidoti | Buy |
| 2016-03-03 | 개시 | H.C. Wainwright | Buy |
모두보기
리간드 파마 주식(LGND)의 최신 뉴스
Ligand's Q2 2025: Unraveling Contradictions in Pelthos Launch, Deal Strategies, and Market Dynamics - AInvest
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript - Insider Monkey
Ligand: RBC Raises PT to $185, Maintains Outperform Rating - AInvest
Ligand Pharma stock price target raised to $185 from $155 at RBC Capital - Investing.com Canada
Ligand Pharmaceuticals Among 3 Stocks Possibly Trading Below Intrinsic Value Estimates - Yahoo Finance
Ligand Pharmaceuticals Q2 2025 Earnings Call Highlights: Robust Royalty Growth and Strategic Partnerships - AInvest
Ligand Pharmaceuticals Raises FY25 EPS and Revenue Outlook, Boosts EPS View to $6.70-$7.00 and Revenue View to $200M-$225M. - AInvest
Ligand Pharmaceuticals Reports Q2 EPS and Revenue Above Consensus, Raises 2025 Guidance - AInvest
Ligand Pharmaceuticals Inc (LGND) Q2 2025 Earnings Call Highlights: Robust Royalty Growth and ... By GuruFocus - Investing.com Canada
Ligand Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Ligand Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Ligand Pharmaceuticals Raises 2025 Revenue Guidance to $225M Amid Royalty Portfolio Momentum - AInvest
Transcript : Ligand Pharmaceuticals Incorporated, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Ligand Pharma stock price target raised to $167 by Oppenheimer on strong royalty growth - Investing.com Canada
Earnings call transcript: Ligand Pharmaceuticals Q2 2025 beats forecasts, stock rises - Investing.com Canada
Ligand Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ligand: Q2 Earnings Snapshot - San Francisco Chronicle
Ligand Q2 2025 presentation: 57% royalty growth drives raised guidance By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $47.6M, EPS Falls Short at $0.24 - GuruFocus
Ligand Pharmaceuticals Reports 57% Increase in Royalty Revenue and Raises 2025 Financial Guidance - Quiver Quantitative
Ligand Pharmaceuticals Q2 revenue up 15%, raises 2025 guidance - MarketScreener
Ligand Q2 revenue up 57% YoY, FY23 guidance raised to $200-$225 mln. - AInvest
Ligand Pharmaceuticals Reports Q2 2025 Financial Results - TradingView
Press Release: Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance - 富途牛牛
Investors in Ligand Pharmaceuticals (NASDAQ:LGND) Have Seen Notable Returns of 36% Over the Past Year - 富途牛牛
Ligand Pharmaceuticals stock hits 52-week high at 143.31 USD By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals stock hits 52-week high at 143.31 USD - Investing.com
Ligand LGND 2025Q2 Earnings Preview Upside Ahead on Robust Revenue Growth - AInvest
Ligand Pharmaceuticals Incorporated Sees Relief Buying After Extended DropReal Trader Watchlist of Hot Stocks Released - metal.it
Price Channel Expanding on Ligand Pharmaceuticals Incorporated’s ChartReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
What is the risk reward ratio of investing in Ligand Pharmaceuticals Incorporated stockHigh-yield investments - Jammu Links News
How does Ligand Pharmaceuticals Incorporated compare to its industry peersDiscover undervalued opportunities early - Jammu Links News
Why is Ligand Pharmaceuticals Incorporated stock attracting strong analyst attentionAchieve rapid financial growth with smart picks - Jammu Links News
What makes Ligand Pharmaceuticals Incorporated stock price move sharplyFastest return on investment - Jammu Links News
Is Ligand Pharmaceuticals Incorporated a good long term investmentCapitalize on momentum-driven opportunities - Jammu Links News
Ligand Pharmaceuticals to meet with Oppenheimer on July 28-29 - AInvest
Ligand Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
Orchestra BioMed secures $70 million from Ligand and Medtronic By Investing.com - Investing.com South Africa
Orchestra BioMed secures $70 million from Ligand and Medtronic - Investing.com
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - GlobeNewswire
$70M Strategic Investment Powers Orchestra BioMed's Revolutionary Leadless Pacemaker Technology - Stock Titan
How Ligand Pharmaceuticals Incorporated stock performs during market volatilityTrend Analysis for Safer Trades Gains Popularity - beatles.ru
When is Ligand Pharmaceuticals Incorporated stock expected to show significant growthSmart Portfolio Planner With Proven Results - Jammu Links News
LGND: Oppenheimer Raises Price Target for Ligand Pharmaceuticals - GuruFocus
Ligand Pharmaceuticals Price Target Raised Amid Positive Developments - AInvest
Oppenheimer Raises Ligand Pharmaceuticals PT to $162 from $145 to Outperform. - AInvest
Oppenheimer raises Ligand Pharma stock price target to $162 on royalty growth - Investing.com Australia
Oppenheimer raises Ligand Pharma stock price target to $162 on royalty growth By Investing.com - Investing.com South Africa
Key External Factors That Drive Ligand Pharmaceuticals Incorporated Stock Price MovementsLow Risk Equity Screener With Results Shared - metal.it
Ligand Pharmaceuticals Incorporated Recovery Likely Here’s What Data ShowsAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Published on: 2025-07-29 17:16:20 - metal.it
리간드 파마 (LGND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):